USD 41.72
↓ -0.46 (-1.09%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RNA | -1.1 | -11.8 | -17.3 | -7.2 | 41.4 | 598.8 | 45.6 | 46.4 | 46.4 | 46.4 |
| S&P 500 | 0.6 | -1.4 | 0.7 | 6.3 | 11.3 | 29.8 | 25.5 | 89.1 | 187.8 | 33335.7 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RNA |
| name | Avidity Biosciences, Inc. |
| price | 41.72 |
| changes percentage | -1.09 |
| change | -0.46 |
| day low | 39.57 |
| day high | 42.32 |
| year high | 56 |
| year low | 5.68 |
| market cap | 4977571480 |
| price avg 50 | 45.26 |
| price avg 200 | 34.39 |
| exchange | NASDAQ |
| volume | 410366 |
| avg volume | 1298943 |
| open | 42.02 |
| previous close | 42.18 |
| eps | -2.88 |
| pe | -14.49 |
| earnings announcement | 2025-02-26T05:00:00.000+0000 |
| shares outstanding | 119309000 |
| timestamp | 2024-11-18 16:47:56 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001599901 | |||
| revenue | 9560000 | 9224000 | 3.64 |
| gross profit | -181408000 | 7837000 | -2,414.76 |
| gross profit ratio | -18.98 | 0.85 | -2,333.41 |
| research and development expenses | 190968000 | 150404000 | 26.97 |
| operating expenses | 245158000 | 188137000 | 30.31 |
| interest income | 23972000 | 4975000 | 381.85 |
| interest expense | 0 | 0 | NaN |
| ebitda | -233497000 | -177526000 | -31.53 |
| ebitdaratio | -24.42 | -19.4 | -25.92 |
| operating income | -235598000 | -178913000 | -31.68 |
| operating income ratio | -24.64 | -19.4 | -27.05 |
| net income | -212220000 | -169077000 | -25.52 |
| net income ratio | -22.2 | -18.33 | -21.11 |
| eps | -2.91 | -3.24 | 10.19 |
Revenue Growth: revenue increased to 10 million in 2023 from 9 million in 2022 representing a change of 3.64%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 191 million in 2023 from 150 million in 2022 representing a change of 26.97%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -233 million in 2023 from -178 million in 2022 representing a change of -31.53%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -236 million in 2023 from -179 million in 2022 representing a change of -31.68%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -212 million in 2023 from -169 million in 2022 representing a change of -25.52%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -2.91 in 2023 from -2.91 in 2022 representing a change of 10.19%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -181 million in 2023 from 8 million in 2022 representing a change of -2414.76%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 245 million in 2023 from 188 million in 2022 representing a change of 30.31%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001599901 | |||
| revenue | 2336000 | 2045000 | 14.23 |
| gross profit | 2336000 | 1358000 | 72.02 |
| gross profit ratio | 1 | 0.66 | 50.59 |
| research and development expenses | 77197000 | 63940000 | 20.73 |
| operating expenses | 100470000 | 84671000 | 18.66 |
| interest income | 17968000 | 11949000 | 50.37 |
| interest expense | 0 | 0 | NaN |
| ebitda | -97424000 | -82626000 | -17.91 |
| ebitdaratio | -41.71 | -40.4 | -3.22 |
| operating income | -98134000 | -82626000 | -18.77 |
| operating income ratio | -42.01 | -40.4 | -3.97 |
| net income | -80398000 | -70793000 | -13.57 |
| net income ratio | -34.42 | -34.62 | 0.58 |
| eps | -0.65 | -0.66 | 1.52 |
Revenue Growth: revenue increased to 2 million in 2024Q3 from 2 million in 2024Q2 representing a change of 14.23%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 2 million in 2024Q3 from 1 million in 2024Q2 representing a change of 72.02%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 77 million in 2024Q3 from 64 million in 2024Q2 representing a change of 20.73%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 100 million in 2024Q3 from 85 million in 2024Q2 representing a change of 18.66%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -97 million in 2024Q3 from -83 million in 2024Q2 representing a change of -17.91%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -98 million in 2024Q3 from -83 million in 2024Q2 representing a change of -18.77%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -80 million in 2024Q3 from -71 million in 2024Q2 representing a change of -13.57%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.65 in 2024Q3 from -0.65 in 2024Q2 representing a change of 1.52%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001599901 | |||
| total assets | 628555000 | 638800000 | -1.60 |
| total liabilities | 127791000 | 60725000 | 110.44 |
| total equity | 500764000 | 578075000 | -13.37 |
| cash and cash equivalents | 185082000 | 340396000 | -45.63 |
| short term investments | 410269000 | 270331000 | 51.77 |
| long term investments | 0 | 251000 | -100.00 |
| total current assets | 611307000 | 622942000 | -1.87 |
| total non current assets | 17248000 | 15858000 | 8.77 |
| total current liabilities | 80680000 | 51908000 | 55.43 |
| total non current liabilities | 47111000 | 8817000 | 434.32 |
| common stock | 8000 | 7000 | 14.29 |
| retained earnings | -570764000 | -358544000 | -59.19 |
| total debt | 9852000 | 10687000 | -7.81 |
Total Assets: Total Assets decreased to 629 million in 2023 from 639 million in 2022 representing a change of -1.6%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 128 million in 2023 from 61 million in 2022 representing a change of 110.44%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 501 million in 2023 from 578 million in 2022 representing a change of -13.37%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 185 million in 2023 from 340 million in 2022 representing a change of -45.63%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 611 million in 2023 from 623 million in 2022 representing a change of -1.87%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 81 million in 2023 from 52 million in 2022 representing a change of 55.43%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -571 million in 2023 from -359 million in 2022 representing a change of -59.19%. This indicates an accumulated losses.
Short Term Investments: Short Term Investments increased to 410 million in 2023 from 270 million in 2022 representing a change of 51.77%. This indicates an increase in short-term investment holdings.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 14.29%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 10 million in 2023 from 11 million in 2022 representing a change of -7.81%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001599901 | |||
| total assets | 1640771000 | 1347425000 | 21.77 |
| total liabilities | 137391000 | 126389000 | 8.70 |
| total equity | 1503380000 | 1221036000 | 23.12 |
| cash and cash equivalents | 370187000 | 575751000 | -35.70 |
| short term investments | 1218406000 | 723295000 | 68.45 |
| long term investments | 0 | 2795000 | -100.00 |
| total current assets | 1621866000 | 1328801000 | 22.05 |
| total non current assets | 18905000 | 18624000 | 1.51 |
| total current liabilities | 91333000 | 84212000 | 8.46 |
| total non current liabilities | 46058000 | 42177000 | 9.20 |
| common stock | 12000 | 11000 | 9.09 |
| retained earnings | -790810000 | -710412000 | -11.32 |
| total debt | 7601000 | 8382000 | -9.32 |
Total Assets: Total Assets increased to 1,641 million in 2024Q3 from 1,347 million in 2024Q2 representing a change of 21.77%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 1,503 million in 2024Q3 from 1,221 million in 2024Q2 representing a change of 23.12%. This indicates an increase in shareholders' equity.
Short Term Investments: Short Term Investments increased to 1,218 million in 2024Q3 from 723 million in 2024Q2 representing a change of 68.45%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,622 million in 2024Q3 from 1,329 million in 2024Q2 representing a change of 22.05%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 9.09%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 8 million in 2024Q3 from 8 million in 2024Q2 representing a change of -9.32%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 137 million in 2024Q3 from 126 million in 2024Q2 representing a change of 8.7%. This indicates an increase in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 370 million in 2024Q3 from 576 million in 2024Q2 representing a change of -35.7%. This indicates a decrease in available liquid assets.
Total Current Liabilities: Total Current Liabilities increased to 91 million in 2024Q3 from 84 million in 2024Q2 representing a change of 8.46%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -791 million in 2024Q3 from -710 million in 2024Q2 representing a change of -11.32%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001599901 | |||
| net change in cash | -155270000 | 19948000 | -878.37 |
| operating cash flow | -119064000 | -136268000 | 12.63 |
| free cash flow | -123292000 | -139091000 | 11.36 |
| capital expenditure | -4228000 | -2823000 | -49.77 |
| depreciation and amortization | 2101000 | 1387000 | 51.48 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 38222000 | 27139000 | 40.84 |
| accounts payables | 1769000 | 18315000 | -90.34 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 187132000 | -100.00 |
| investments in property plant and equipment | -4228000 | -2823000 | -49.77 |
| net cash used for investing activites | -130070000 | -189955000 | 31.53 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 60547000 | 344779000 | -82.44 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 93864000 | 346171000 | -72.89 |
| cash at end of period | 185377000 | 340647000 | -45.58 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 340647000 | 320699000 | 6.22 |
Net Change in Cash: Net Change in Cash decreased to -155 million in 2023 from 20 million in 2022 representing a change of -878.37%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 38 million in 2023 from 27 million in 2022 representing a change of 40.84%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow increased to -119 million in 2023 from -136 million in 2022 representing a change of 12.63%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -123 million in 2023 from -139 million in 2022 representing a change of 11.36%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -4 million in 2023 from -3 million in 2022 representing a change of -49.77%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 2 million in 2023 from 18 million in 2022 representing a change of -90.34%. This indicates that the company has reduced its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001599901 | |||
| operating cash flow | -65615000 | -65004000 | -0.94 |
| free cash flow | -67319000 | -65535000 | -2.72 |
| capital expenditure | -1704000 | -531000 | -220.90 |
| depreciation and amortization | 710000 | 687000 | 3.35 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 14092000 | 12812000 | 9.99 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | 8675000 | 3472000 | 149.86 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -1704000 | -531000 | -220.90 |
| net cash used for investing activites | -482413000 | -274869000 | -75.51 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 465154000 | 433049000 | 7.41 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 342464000 | 446724000 | -23.34 |
| net change in cash | -205564000 | 104351000 | -296.99 |
| cash at end of period | 372982000 | 575751000 | -35.22 |
| cash at beginning of period | 578546000 | 471400000 | 22.73 |
Net Change in Cash: Net Change in Cash decreased to -206 million in 2024Q3 from 104 million in 2024Q2 representing a change of -296.99%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -66 million in 2024Q3 from -65 million in 2024Q2 representing a change of -0.94%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -67 million in 2024Q3 from -66 million in 2024Q2 representing a change of -2.72%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 14 million in 2024Q3 from 13 million in 2024Q2 representing a change of 9.99%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 9 million in 2024Q3 from 3 million in 2024Q2 representing a change of 149.86%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to -2 million in 2024Q3 from -1 million in 2024Q2 representing a change of -220.9%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2014 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.13 | 0.18 | -25.95 |
| net income per share | -2.91 | -3.24 | 10.33 |
| operating cash flow per share | -1.63 | -2.61 | 37.58 |
| free cash flow per share | -1.69 | -2.67 | 36.67 |
| cash per share | 8.15 | 11.71 | -30.36 |
| book value per share | 6.86 | 11.08 | -38.11 |
| tangible book value per share | 6.86 | 11.08 | -38.11 |
| shareholders equity per share | 6.86 | 11.08 | -38.11 |
| interest debt per share | 0.13 | 0.2 | -34.14 |
| market cap | 660758600 | 1157474780 | -42.91 |
| enterprise value | 485528600 | 827765780 | -41.34 |
| pe ratio | -3.11 | -6.85 | 54.52 |
| price to sales ratio | 69.12 | 125.49 | -44.92 |
| pocfratio | -5.55 | -8.49 | 34.67 |
| pfcf ratio | -5.36 | -8.32 | 35.60 |
| pb ratio | 1.32 | 2.0 | -34.10 |
| ptb ratio | 1.32 | 2.0 | -34.10 |
| ev to sales | 50.79 | 89.74 | -43.41 |
| enterprise value over ebitda | -2.08 | -4.66 | 55.40 |
| ev to operating cash flow | -4.08 | -6.07 | 32.87 |
| ev to free cash flow | -3.94 | -5.95 | 33.83 |
| earnings yield | -0.32 | -0.15 | -119.87 |
| free cash flow yield | -0.19 | -0.12 | -55.28 |
| debt to equity | 0.02 | 0.02 | 6.42 |
| debt to assets | 0.02 | 0.02 | -6.31 |
| net debt to ebitda | 0.75 | 1.86 | -59.59 |
| current ratio | 7.58 | 12.0 | -36.86 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.56 | 0.78 | -28.36 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 5.67 | 4.09 | 38.57 |
| research and ddevelopement to revenue | 19.98 | 16.31 | 22.51 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.04 | -0.02 | -71.41 |
| capex to revenue | 0.44 | 0.31 | 44.51 |
| capex to depreciation | 2.01 | 2.04 | -1.13 |
| stock based compensation to revenue | 4.0 | 2.94 | 35.89 |
| graham number | 21.18 | 28.43 | -25.50 |
| roic | -0.46 | -0.3 | -56.25 |
| return on tangible assets | -0.34 | -0.26 | -27.56 |
| graham net net | 6.49 | 10.54 | -38.43 |
| working capital | 530627000 | 571034000 | -7.08 |
| tangible asset value | 500764000 | 578075000 | -13.37 |
| net current asset value | 483516000 | 562217000 | -14.00 |
| invested capital | 547279000 | 586043000 | -6.61 |
| average receivables | 4311500 | 450000 | 858.11 |
| average payables | 6723000 | 3721500 | 80.65 |
| average inventory | 0.5 | -449999.5 | 100.00 |
| days sales outstanding | 329.23 | 0 | NaN |
| days payables outstanding | 16.84 | 1220.26 | -98.62 |
| days of inventory on hand | 0 | 0.0 | -100.00 |
| receivables turnover | 1.11 | 0 | NaN |
| payables turnover | 21.68 | 0.3 | 7,147.61 |
| inventory turnover | 0 | 1387000 | -100.00 |
| roe | -0.42 | -0.29 | -44.89 |
| capex per share | 0.06 | 0.05 | 7.00 |
ROE: Return on Equity (ROE) decreased to -0.42 on 2023-12-31 from -0.29 on 2022-12-31, representing a change of -44.89%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 7.58 on 2023-12-31 from 12.00 on 2022-12-31, representing a change of -36.86%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -3.11 on 2023-12-31 from -6.85 on 2022-12-31, representing a change of 54.52%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.02 on 2023-12-31 from 0.02 on 2022-12-31, representing a change of 6.42%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RNA | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.02 | 0.02 | -1.00 |
| net income per share | -0.65 | -0.66 | 1.57 |
| operating cash flow per share | -0.53 | -0.61 | 12.52 |
| free cash flow per share | -0.55 | -0.61 | 10.97 |
| cash per share | 12.88 | 12.15 | 5.99 |
| book value per share | 12.19 | 11.42 | 6.71 |
| tangible book value per share | 12.19 | 11.42 | 6.71 |
| shareholders equity per share | 12.19 | 11.42 | 6.71 |
| interest debt per share | 0 | 0.04 | -100.00 |
| market cap | 5666613750 | 4413987840 | 28.38 |
| enterprise value | 5304027750 | 3846618840 | 37.89 |
| pe ratio | -17.62 | -15.59 | -13.04 |
| price to sales ratio | 2425.78 | 2158.43 | 12.39 |
| pocfratio | -86.36 | -67.9 | -27.18 |
| pfcf ratio | -84.18 | -67.35 | -24.98 |
| pb ratio | 3.77 | 3.61 | 4.27 |
| ptb ratio | 3.77 | 3.61 | 4.27 |
| ev to sales | 2270.56 | 1880.99 | 20.71 |
| enterprise value over ebitda | -54.44 | -46.55 | -16.94 |
| ev to operating cash flow | -80.84 | -59.18 | -36.60 |
| ev to free cash flow | -78.79 | -58.7 | -34.23 |
| earnings yield | -0.01 | -0.02 | 11.54 |
| free cash flow yield | -0.01 | -0.01 | 19.98 |
| debt to equity | 0 | 0.0 | -100.00 |
| debt to assets | 0 | 0.0 | -100.00 |
| net debt to ebitda | 3.72 | 6.87 | -45.80 |
| current ratio | 17.76 | 15.78 | 12.54 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.82 | 0.92 | -11.12 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 9.96 | 10.14 | -1.72 |
| research and ddevelopement to revenue | 33.05 | 31.27 | 5.69 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.03 | -0.01 | -217.92 |
| capex to revenue | 0.73 | 0.26 | 180.93 |
| capex to depreciation | 2.4 | 0.77 | 210.51 |
| stock based compensation to revenue | 6.03 | 6.27 | -3.71 |
| graham number | 13.37 | 13.04 | 2.49 |
| roic | -0.07 | -0.07 | 3.24 |
| return on tangible assets | -0.05 | -0.05 | 6.74 |
| graham net net | 11.88 | 10.97 | 8.32 |
| working capital | 1530533000 | 1244589000 | 22.97 |
| tangible asset value | 1503380000 | 1221036000 | 23.12 |
| net current asset value | 1484475000 | 1202412000 | 23.46 |
| invested capital | 1546325000 | 1260054000 | 22.72 |
| average receivables | 9605000 | 787500 | 1,119.68 |
| average payables | 8275500 | 5619000 | 47.28 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 740.11 | 0 | NaN |
| days payables outstanding | 0 | 1164.5 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0.12 | 0 | NaN |
| payables turnover | 0 | 0.08 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.05 | -0.06 | 7.76 |
| capex per share | 0.01 | 0.0 | 178.12 |
ROE: Return on Equity (ROE) increased to -0.05 on 2024-09-30 Q3 from -0.06 on 2024-06-30 Q2, representing a change of 7.76%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -17.62 on 2024-09-30 Q3 from -15.59 on 2024-06-30 Q2, representing a change of -13.04%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 17.76 on 2024-09-30 Q3 from 15.78 on 2024-06-30 Q2, representing a change of 12.54%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of -100.00%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -4.09 which is lower than current price 41.72, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-14 09:41:18
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Sentiment: Positive
Publish Date: 2024-11-13 11:24:41
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's Business Daily.
Sentiment: Positive
Publish Date: 2024-11-12 07:00:00
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 Volume 11 of virtual investor and analyst series today, Tuesday, Nov. 12 at 8:00 a.m. ET SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart.
Sentiment: Negative
Publish Date: 2024-11-07 19:10:25
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-07 16:05:00
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. "We are executing three potentially registrational clinical trials in three rare diseases where there are limited or no therapeutic options available.
Sentiment: Positive
Publish Date: 2024-11-06 11:05:28
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment: Positive
Publish Date: 2024-10-31 09:00:00
Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will share new development candidates from its precision cardiology portfolio and provide a first look at its next-generation technology innovations.
Sentiment: Positive
Publish Date: 2024-10-21 16:05:00
SAN DIEGO , Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 421,600 shares of its common stock and 210,800 restricted stock units ("RSUs") to thirty-four (34) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Positive
Publish Date: 2024-10-04 19:00:02
The company's most promising pipeline program can continue unabated.
Sentiment: Positive
Publish Date: 2024-09-25 09:00:00
SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference: Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m.
Sentiment: Positive
Publish Date: 2024-09-24 14:15:49
Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-to-market commercial opportunities for its investigational candidates.
Sentiment: Positive
Publish Date: 2024-09-23 16:05:00
SAN DIEGO , Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 212,000 shares of its common stock and 106,000 restricted stock units ("RSUs") to twenty-one (21) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan").
Sentiment: Positive
Publish Date: 2024-09-08 07:43:58
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.
Sentiment: Positive
Publish Date: 2024-09-05 09:00:00
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) SAN DIEGO , Sept. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining with patient and advocacy communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families who are impacted by neuromuscular diseases.
Sentiment: Positive
Publish Date: 2024-08-28 09:00:00
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m.
Sentiment: Positive
Publish Date: 2024-08-21 16:05:00
SAN DIEGO , Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 52,100 shares of its common stock and 26,050 restricted stock units ("RSUs") to seven (7) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
